Journal
CANCERS
Volume 13, Issue 19, Pages -Publisher
MDPI
DOI: 10.3390/cancers13194984
Keywords
pancreatic cancer; TGF beta; stroma; fibroblasts; CAFs
Categories
Funding
- Cancer Research UK [A17196, A29996, A23526, A31287]
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma is an aggressive disease with limited available therapies, notable for its high tumour complexity and recent findings on the intricacy of signalling within the stroma, particularly the molecular and functional heterogeneity of cancer associated fibroblasts. While some progress has been made, there are still considerable gaps in our knowledge that require further research efforts.
Pancreatic ductal adenocarcinoma is an aggressive disease for which there are very few available therapies. It is notable for its high degree of tumour complexity, with the tumour microenvironment often accounting for the majority of the tumour volume. Until recently, the biology of the stroma was poorly understood, particularly in terms of heterogeneity. Recent research, however, has shed light on the intricacy of signalling within the stroma and particularly the molecular and functional heterogeneity of the cancer associated fibroblasts. In this review, we summarise the recent improvements in our understanding of the different fibroblast populations within PDAC, with a focus on the role TGF beta plays to dictate their formation and function. These studies have highlighted some of the reasons for the failure of trials targeting the tumour stroma, however, there are still considerable gaps in our knowledge, and more work is needed to make effective fibroblast targeting a reality in the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available